22.418 articles found

Derivatives of N-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics

DARGAZANLI GIHAD, ESTENNE-BOUHTOU GENEVIEVE, VERONIQUE CORINNE.

· 2006-04-17

Derivatives of N-[phenyl(pyrrolidine-2-yl)methyl]benzamide and N-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics

DARGAZANLI GIHAD, ESTENNE-BOUHTOU GENEVIEVE, MEDAISKO FLORENCE, RAKOTOARISOA NATHALIE.

· 2006-04-17

Derivatives of N-[heteroaryl(piperidine-2-yl) methyl]benzamide, preparation method thereof and application of same in therapeutics

DARGAZANLI GIHAD, ESTENNE-BOUHTOU GENEVIEVE, MEDAISKO FLORENCE, RENONES MARIA-CARMEN.

· 2006-04-17

Derivatives of N-[heteroaryl(piperidine-2-yl) methyl]benzamide, preparation method thereof and application of same in therapeutics

DARGAZANLI GIHAD, ESTENNE-BOUHTOU GENEVIEVE, MEDAISKO FLORENCE, RENONES MARIA-CARMEN.

· 2006-04-17

Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.

Müller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Goetze O, Woitalla D.

J Neural Transm (Vienna) · 2006-04-11

DOI: 10.1007/s00702-006-0442-5PMID: 16604302

Pharmaceutical composition containing obovatol as an active ingredient for the prevention and treatment of neurodegenerative diseases

KWON BYOUNG-MOG, SON KWANG-HEE, HAN DONG C, LEE JI-MIN, SUK KYOUNGHO, HONG SU H, OCK JIYEON.

· 2006-04-10

Cyclic G-2AllylProline in treatment of Parkinson's disease

BRIMBLE MARGARET A, GUAN JIAN.

· 2006-04-07

Inositol and IP3 levels regulate autophagy: biology and therapeutic speculations.

Sarkar S, Rubinsztein DC.

Autophagy · 2006-04-06

DOI: 10.4161/auto.2387PMID: 16874097

Exo-S-Mecamylamine Formulation and Use in Treatment

SHYTLE DOUGLAS, SANBERG PAUL, NEWMAN MARY, SILVER ARCHIE A.

· 2006-04-05

Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.

Poewe W, Wolters E, Emre M, Onofrj M, Hsu C, Tekin S, Lane R, EXPRESS Investigators.

Mov Disord · 2006-04-01

DOI: 10.1002/mds.20700PMID: 16229010

The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.

Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, Aguilar M, Del Signore S, Cesaro P, Parkinson-Control Study Group.

Mov Disord · 2006-04-01

DOI: 10.1002/mds.20750PMID: 16267842

Endogenous melatonin protects L-DOPA from autoxidation in the striatal extracellular compartment of the freely moving rat: potential implication for long-term L-DOPA therapy in Parkinson's disease.

Rocchitta G, Migheli R, Esposito G, Marchetti B, Desole MS, Miele E, Serra PA.

J Pineal Res · 2006-04-01

DOI: 10.1111/j.1600-079x.2005.00299.xPMID: 16499555